Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/novel-targets-for-treatment-of-adult-acute-lymphocytic-leukemia-ISYOLE10xB
References (50)
-
M. Bjornsti, P. Houghton (2004)
The tor pathway: a target for cancer therapyNature Reviews Cancer, 4
-
Yanping Hu, M. Turner, J. Shields, M. Gale, E. Hutto, B. Roberts, W. Siders, J. Kaplan (2009)
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse modelImmunology, 128
-
Kathleen Cullion, K. Draheim, N. Hermance, J. Tammam, V. Sharma, C. Ware, G. Nikov, Veena Krishnamoorthy, P. Majumder, M. Kelliher (2009)
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.Blood, 113 24
-
Savita Bhalla, R. Gartenhaus, B. Dai, S. Prachand, Arindam Mukherjee, R. Elstrom, L. Gordon, A. Evens (2009)
The Novel 2nd Generation Small Molecule MEK Inhibitor, AZD-6244, Induces Cell Death in Lymphoma Cells Lines, Primary Cells, and in a Human Lymphoma Xenograft Model.Blood, 114
-
E. Raetz, M. Cairo, M. Borowitz, S. Blaney, M. Krailo, T. Leil, J. Reid, D. Goldenberg, W. Wegener, W. Carroll, P. Adamson (2008)
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 22
-
M. Coleman, D. Goldenberg, A. Siegel, Jamie Ketas, Michelle Ashe, J. Fiore, J. Leonard (2003)
Epratuzumab: targeting B-cell malignancies through CD22.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 10 Pt 2
-
C. Nabhan, D. Patton, L. Gordon, M. Riley, T. Kuzel, M. Tallman, S. Rosen (2004)
A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)Leukemia & Lymphoma, 45
-
(2010)
University Hospitals: Trial for treatment of adult patients with standard risk acute lymphoblastic leukemia with chemotherapy and rituximab -
Yttrium Y 90 anti - CD 19 antibody BU - 12 in patients with advanced relapsed or refractory acute lymphoblastic leukemia or chronic lymphocytic leukemia -
M Majewski, M Korecka, P Kossev (2000)
The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disordersProc Natl Acad Sci U S A, 97
-
VI Brown, J Fang, K Alcorn (2003)
Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signalingProc Natl Acad Sci U S A, 100
-
C. Punt, J. Boni, U. Bruntsch, M. Peters, C. Thielert (2003)
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.Annals of oncology : official journal of the European Society for Medical Oncology, 14 6
-
SM Ansell, DJ Inwards, KM Rowland (2008)
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupCancer, 113
-
Brian Garibaldi, Rupal Malani, Hsin‐Chieh Yeh, Evan Lipson, Deborah Michell, Mosi Bennett, A. Moliterno, M. McDevitt, T. Kickler (2009)
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab‐ozogamicin in adult refractory B‐acute lymphoblastic leukemiaAmerican Journal of Hematology, 84
-
M. Atkins, M. Hidalgo, W. Stadler, T. Logan, J. Dutcher, G. Hudes, Young Park, S. Liou, Bonnie Marshall, J. Boni, G. Dukart, M. Sherman (2004)
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 5
-
Christophe Frémin, S. Meloche (2010)
From basic research to clinical development of MEK1/2 inhibitors for cancer therapyJournal of Hematology & Oncology, 3
-
D. Thomas, S. O'brien, J. Jorgensen, J. Cortes, S. Faderl, G. Garcia-Manero, S. Verstovsek, C. Koller, S. Pierce, Y. Huh, W. Wierda, M. Keating, H. Kantarjian (2009)
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.Blood, 113 25
-
D. Thomas, S. Faderl, S. O'brien, C. Bueso-Ramos, J. Cortes, G. Garcia-Manero, F. Giles, S. Verstovsek, W. Wierda, S. Pierce, J. Shan, M. Brandt, F. Hagemeister, M. Keating, F. Cabanillas, H. Kantarjian (2006)
Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemiaCancer, 106
-
E. Weidmann, G. Hess, K. Chow, S. Krause, M. Subklewe, J. Kruse, K. Weisel, M. Soekler, Soo‐Zin Kim, S. Napieralski, J. Rech, M. Dreyling, E. Jäger, P. Mitrou (2010)
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomasLeukemia & Lymphoma, 51
-
S. Ansell, D. Inwards, K. Rowland, P. Flynn, R. Morton, D. Moore, S. Kaufmann, I. Ghobrial, Paul Kurtin, M. Maurer, C. Allmer, T. Witzig (2008)
Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphomaCancer, 113
-
N. Gökbuget, D. Hoelzer (1999)
Treatment of adult acute lymphoblastic leukemia.Hematology. American Society of Hematology. Education Program
-
A. Weng, A. Ferrando, W. Lee, John Morris, L. Silverman, Cheryll Sanchez-Irizarry, S. Blacklow, A. Look, J. Aster (2004)
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic LeukemiaScience, 306
-
D. Teachey, Dana Obzut, Jonathan Cooperman, Junjie Fang, M. Carroll, J. Choi, P. Houghton, V. Brown, S. Grupp (2006)
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.Blood, 107 3
-
V. Brown, Junjie Fang, K. Alcorn, R. Barr, Jenny Kim, R. Wasserman, S. Grupp (2003)
Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signalingProceedings of the National Academy of Sciences of the United States of America, 100
-
T. Robak (2008)
Alemtuzumab for B-cell chronic lymphocytic leukemiaExpert Review of Anticancer Therapy, 8
-
D. Teachey, C. Sheen, Junior Hall, T. Ryan, V. Brown, J. Fish, G. Reid, A. Seif, R. Norris, Yueh Chang, M. Carroll, S. Grupp (2008)
mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.Blood, 112 5
-
W. Stock, B. Sanford, G. Lozanski, R. Vij, J. Byrd, B. Powell, M. Wetzler, D. Sher, C. Edwards, M. Kelly, S. Richards, Crystal Sung, G. Malnassy, E. Hoke, C. Bloomfield, R. Larson (2009)
Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).Blood, 114
-
Frédéric Lajaunias, L. Nitschke, T. Moll, E. Martínez-Soria, I. Semac, Y. Chicheportiche, R. Parkhouse, S. Izui (2002)
Differentially Regulated Expression and Function of CD22 in Activated B-1 and B-2 Lymphocytes1The Journal of Immunology, 168
-
P. Real, A. Ferrando, A. Ferrando (2009)
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemiaLeukemia, 23
-
N Gokbuget, D Hoelzer (2009)
Treatment of adult acute lymphoblastic leukemiaSemin Hematol, 46
-
T. Hansel, H. Kropshofer, T. Singer, J. Mitchell, A. George (2010)
The safety and side effects of monoclonal antibodiesNature Reviews Drug Discovery, 9
-
O. Gautschi, J. Heighway, P. Mack, P. Purnell, P. Lara, D. Gandara (2008)
Aurora Kinases as Anticancer Drug TargetsClinical Cancer Research, 14
-
K. Keersmaecker, I. Lahortiga, N. Mentens, Cedric Folens, L. Neste, S. Bekaert, P. Vandenberghe, M. Odero, P. Marynen, J. Cools (2008)
In vitro validation of γ-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemiaHaematologica, 93
-
Michael Wang, L. Fayad, F. Cabanillas, F. Hagemeister, P. Mclaughlin, Maria Rodriguez, L. Kwak, Yuhong Zhou, H. Kantarjian, J. Romaguera (2008)
Phase 2 trial of rituximab plus hyper‐CVAD alternating with rituximab plus methotrexate‐cytarabine for relapsed or refractory aggressive mantle cell lymphomaCancer, 113
-
M. Majewski, M. Korecka, P. Kossev, Shiyong Li, June Goldman, Jonni Moore, L. Silberstein, P. Nowell, W. Schuler, Leslie Shaw, M. Wasik (2000)
The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.Proceedings of the National Academy of Sciences of the United States of America, 97 8
-
A. Perl, M. Kasner, D. Tsai, D. Vogl, A. Loren, S. Schuster, D. Porter, E. Stadtmauer, S. Goldstein, N. Frey, S. Nasta, E. Hexner, J. Dierov, C. Swider, A. Bagg, A. Gewirtz, M. Carroll, S. Luger (2009)
A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous LeukemiaClinical Cancer Research, 15
-
K. Tanigaki, T. Honjo (2007)
Regulation of lymphocyte development by Notch signalingNature Immunology, 8
-
Iwan Beuvink, A. Boulay, S. Fumagalli, Frédéric Zilbermann, S. Ruetz, T. O'reilly, F. Natt, Jonathan Hall, H. Lane, G. Thomas (2005)
The mTOR Inhibitor RAD 001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p 21 Translation -
(2010)
Cancer Center: Modified Hyper-CVAD (cyclophosphamide, vincristine, Adriamycin, and dexamethasone) program for acute lymphoblastic leukemia -
A. Fielding, S. Richards, R. Chopra, H. Lazarus, M. Litzow, G. Buck, I. Durrant, S. Luger, D. Marks, I. Franklin, A. McMillan, M. Tallman, J. Rowe, A. Goldstone (2007)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.Blood, 109 3
-
L. Elit (2002)
CCI-779 Wyeth.Current opinion in investigational drugs, 3 8
-
Standard chemotherapy with or without nelarabine or epratuzumab and / or rituximab in treating patients with newly diagnosed acute lymphoblastic leukemia -
Qing Xu, S. Simpson, T. Scialla, A. Bagg, M. Carroll (2003)
Survival of acute myeloid leukemia cells requires PI3 kinase activation.Blood, 102 3
-
F. Armstrong, P. Grange, Bastien Gerby, M. Rouyez, J. Calvo, M. Fontenay, N. Boissel, H. Dombret, A. Baruchel, J. Landman-Parker, P. Romeo, P. Ballerini, F. Pflumio (2009)
NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity.Blood, 113 8
-
A. Fielding (2008)
The treatment of adults with acute lymphoblastic leukemia.Hematology. American Society of Hematology. Education Program
-
P. Real, V. Tosello, T. Palomero, M. Castillo, E. Hernando, E. Stanchina, M. Sulis, Kelly Barnes, Catherine Sawai, I. Homminga, J. Meijerink, I. Aifantis, G. Basso, C. Cordon-Cardo, W. Ai, A. Ferrando (2008)
Gamma-secretase inhibitors reverse glucocorticoid resistance in T-ALLNature medicine, 15
-
T. Palomero, A. Ferrando (2009)
Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.Clinical lymphoma & myeloma, 9 Suppl 3
-
PJ Real, V Tosello, T Palomero (2009)
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemiaNat Med, 15
-
Iwan Beuvink, A. Boulay, S. Fumagalli, Frédéric Zilbermann, S. Ruetz, T. O'reilly, F. Natt, Jonathan Hall, H. Lane, G. Thomas (2005)
The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 TranslationCell, 120
-
H. Horton, M. Bernett, E. Pong, M. Peipp, S. Karki, S. Chu, J. Richards, I. Voštiar, Patrick Joyce, R. Repp, J. Desjarlais, E. Zhukovsky (2008)
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.Cancer research, 68 19
- Publisher
- Springer Journals
- Copyright
- Copyright © Springer Science+Business Media, LLC 2010
- Subject
- Medicine & Public Health; Hematology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-010-0064-8
- pmid
- 20680526
- Publisher site
- See Article on Publisher Site
Abstract
The treatment of acute lymphocytic leukemia (ALL) results in long-term disease-free survival in only 30–40% of adults. Conventional chemotherapy is toxic and woefully ineffective. Therefore, novel agents are being investigated. Among these agents are monoclonal antibodies such as rituximab, epratuzumab, and alemtuzumab and targeted therapies such as tyrosine kinase inhibitors, mTOR inhibitors, and mitogen-activated protein kinase (MEK) inhibitors. This article discusses such novel targets for the treatment of ALL.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Oct 1, 2010
Keywords: Acute lymphocytic leukemia; Philadelphia+; Molecular targets; Tyrosine kinase inhibitors; Monoclonal antibodies; mTOR; Notch; CD19; CD20; CD22; CD52; Rapamycin; MEK